Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 secukinumab with prednisone taper for giant cell arteritis
MOH_2022-11-27_012199Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab and prednisone in giant cell arteritis (GCA) (3 arms), sponsored by Novartis. Started Feb 2023; status: completed.
02
Drugs
secukinumabprednisone
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on MOH_2022-11-27_012199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-27_012199.